VitaStemPrice

(VITASTEM)

VitaStem is a pioneering longevity project within the Decentralized Science (DeSci) sector. It utilizes advanced artificial intelligence to discover methods for rejuvenating human Hematopoietic Stem Cells (HSCs). Unlike traditional approaches that view aging as a single defect, VitaStem treats it as a series of convergent damages across metabolic and epigenetic systems. By targeting these systems, the project aims to develop therapies that can restore stem cell function and extend human healthspan through a decentralized, community-driven research framework.

An IP-Token (IPT) is a novel asset class in the DeSci ecosystem that represents decentralized ownership and governance rights over Intellectual Property (IP). In the case of VitaStem, the IPT allows holders to govern the IP and scientific data generated during the research process. This model democratizes access to scientific breakthroughs, allowing a global community to participate in the funding, direction, and eventual commercialization of research that was traditionally restricted to centralized institutions or private pharmaceutical companies.

VitaStem is a collaborative effort involving Aubrai, an AI-enabled scientific agent, along with the Bio Protocol and the Molecule infrastructure. The project benefits from the scientific oversight of renowned longevity researchers such as Dr. Aubrey de Grey. By combining AI-driven research with a decentralized infrastructure, the project ensures that its scientific goals are both ambitious and rigorously vetted by experts in the field of regenerative medicine and biogerontology.

The VITASTEM token offers significant utility beyond simple transactions. Holders possess governance rights, allowing them to vote on the project's future research directions and milestones. Additionally, token holders gain access to the extensive multi-omics data produced by the research. Most importantly, the token represents a stake in the potential future commercialization of any rejuvenation therapies or scientific discoveries made by the project, aligning the interests of researchers and the community.

VitaStem has successfully completed its "in-silico" phase, which involved the AI-driven analysis of over 850,000 human stem cell transcriptomes to identify more than 100 rejuvenation target genes. The upcoming roadmap includes "in-vitro" validation between Q4 2025 and Q2 2026, where identified genes will be tested in laboratory-grown stem cells. By Q3 2026, the project plans to move into intervention studies using small molecules and gene activation to validate these rejuvenation targets.

VITASTEM is hosted on the Base network, a high-performance Layer 2 solution. To manage your tokens, ensure your digital wallet is configured for the Base network. You can then import the token using its official contract address: 0x5D4d25810237E4C4869c844be71aA3b1B2dcD3. For trading, users can utilize supported decentralized trading platforms or centralized exchanges like LBank. Always verify contract addresses through official project channels to maintain security and avoid fraudulent activities.